Associated Papers
A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer.
Foote JB et al.
Biorxiv : the Preprint Server for Biology, 2024
The Pan-RAF-MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS-MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers.
Ryan MB et al.
Cancer Discovery, 2024
38588399 (PubMed )
Supplement: cd-24-0139_supplementary_table_6_suppst6.xlsx › OMNI
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Holderfield M et al.
Nature, 2024
38589574 (PubMed )
Supplement: 41586_2024_7205_MOESM5_ESM.xlsx › Additional_Cell_Panel_Data
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
35244186 (PubMed )
Supplement: Supplementary_Data2.xlsx › Feuil1
Development and evaluation of ActSeq: A targeted next-generation sequencing panel for clinical oncology use.
Shi Z et al.
Plos One, 2022
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
33226070 (PubMed )
Supplement: btaa972_supplementary_data.zip › RAS_Manuscript_RMarkdown.tar.gz › RAS_Manuscript1.Revised › RAS_Variants_Scores.xlsx › Sheet1
The Claudin-Low Subtype of High-Grade Serous Ovarian Carcinoma Exhibits Stem Cell Features.
Romani C et al.
Cancers, 2021
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Hao HX et al.
Molecular Cancer Therapeutics, 2019
31439712 (PubMed )
Supplement: 15357163mct190170-sup-217436_2_supp_5691166_pvrtk4.xlsx › PTPN11_shRNA_data
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.
Sun C et al.
Cancer Cell, 2018
Clinical mutational profiling of 1006 lung cancers by next generation sequencing.
Illei PB et al.
Oncotarget, 2017
29228562 (PubMed )
Supplement: oncotarget-08-96684-s001.pdf
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.
Sun C et al.
Science Translational Medicine, 2017
Haploinsufficiency networks identify targetable patterns of allelic deficiency in low mutation ovarian cancer.
Delaney JR et al.
Nature Communications, 2017
28198375 (PubMed )
Supplement: ncomms14423-s1.pdf
Targeted exome sequencing reveals distinct pathogenic variants in Iranians with colorectal cancer.
Ashktorab H et al.
Oncotarget, 2017
28002797 (PubMed )
Supplement: oncotarget-08-7852-s002.xlsx › KRAS.Ion
Heterogeneity of resistance mutations detectable by nextgeneration sequencing in TKI-treated lung adenocarcinoma.
Belchis DA et al.
Oncotarget, 2016
LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer.
Melloni GE et al.
Bmc Bioinformatics, 2016
26860319 (PubMed )
Supplement: 12859_2016_935_MOESM2_ESM.xlsx › Table_S5
Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines.
Vartanian S et al.
The Journal of Biological Chemistry, 2013
Select a paper to view details